Close Menu

NEW YORK (GenomeWeb) – OpGen reported after the close of the market Tuesday that its fourth quarter revenues fell 23 percent year over year.

For the three months ended Dec. 31, 2018, OpGen logged $758,959 in revenues compared to $990,912 in the year-ago quarter.

Fourth quarter product sales fell 6 percent to $589,749 from $626,498; laboratory services revenue ticked up 34 percent to $12,510 from $935; and collaboration revenue dropped 57 percent to $156,700 from $363,479.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

At a meeting this week, researchers and others discussed the regulatory oversight needed for germline genome editing.

The US Food and Drug Administration has asked questions about Myriad Genetics' GeneSight test, according to Bloomberg.

Researchers report that neutrophil extracellular traps appear to binds gallstones together, according to New Scientist.

In Science this week: approach to infer genotype-by-environment interaction from genetic variants associated with phenotypic variability, and more.